Immunogenicity Testing and Antibody Humanization
Antitope is pioneering a new generation of immunogenicity testing, antibody humanization and protein engineering technologies.
Our mission is to apply these technologies to create improved non-immunogenic biologics. Formed in 2004, Antitope provides proprietary technologies as a comprehensive service for the preclinical prediction of clinical immunogenicity, and for the generation of humanized antibodies, therapeutic proteins and recombinant vaccines. To date, we have entered into multiple agreements with pharmaceutical and biotechnology companies worldwide to apply our technologies for the development of improved biologics.
Antitope is part of the PolyTherics group, a leading provider of solutions to enable the development of better biopharmaceuticals.
News & Press
Antitope Strengthens Patent Estate Covering Core Technology for Humanisation/Deimmunisation of Antibodies and Proteins
Cambridge UK, 10 March 2014 - Antitope Ltd (“Antitope”), a PolyTherics company, today announces that the core patent covering its Composite Human...
Antitope Announces Research Agreement with ChemomAb for Generation of Composite Human Antibodies against Inflammatory Diseases
Antitope Announces Research Agreement with ChemomAb for Generation of Composite Human Antibodies against Inflammatory Diseases Cambridge UK, 30 July 2013 –...